ironwood pharmaceuticals (nasdaq: irwd) is focused on creating medicines that make a difference for patients, building value to earn the continued support of our fellow shareholders, and empowering our passionate team to keep doing these two things again and again as we continue to build a leading gastrointestinal therapeutics company. we discovered, developed and are commercializing a medicine for the treatment of adults suffering from irritable bowel syndrome with constipation (ibs-c) or chronic idiopathic constipation (cic). we are also developing a rich pipeline of programs seeking to address patient needs across the upper and lower gastrointestinal tract. our pipeline priorities include exploring further opportunities for our lead medicine, as well as leveraging our therapeutic expertise in gastrointestinal disorders and our pharmacologic expertise in guanylate cyclases to advance multiple investigational medicines. ironwood was founded in 1998 out of the whitehead institute for b

Company profile
Ticker
IRWD
Exchange
Website
CEO
Mark Mallon
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
43404176
IRWD stock data
Latest filings (excl ownership)
8-K/A
Index to Financial Statements
11 Sep 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
8-K
Ironwood Pharmaceuticals Reports Second Quarter 2023 Results; Raises Full Year 2023 LINZESS® U.S. Net Sales and Ironwood Revenue Guidance
8 Aug 23
8-K
Ironwood and VectivBio Announce the Completion of the Tender Offer for VectivBio Shares
30 Jun 23
SC TO-T/A
Third party tender offer statement (amended)
29 Jun 23
SC TO-T/A
Third party tender offer statement (amended)
26 Jun 23
8-K
Departure of Directors or Certain Officers
22 Jun 23
SC TO-T/A
Third party tender offer statement (amended)
20 Jun 23
SC TO-T/A
Third party tender offer statement (amended)
16 Jun 23
SC TO-T
Third party tender offer statement
31 May 23
Transcripts
IRWD
Earnings call transcript
2023 Q2
8 Aug 23
IRWD
Earnings call transcript
2022 Q4
16 Feb 23
IRWD
Earnings call transcript
2022 Q3
3 Nov 22
IRWD
Earnings call transcript
2022 Q2
6 Aug 22
IRWD
Earnings call transcript
2022 Q1
8 May 22
IRWD
Earnings call transcript
2021 Q4
17 Feb 22
IRWD
Earnings call transcript
2021 Q3
6 Nov 21
IRWD
Earnings call transcript
2021 Q2
8 Aug 21
IRWD
Earnings call transcript
2021 Q1
9 May 21
IRWD
Earnings call transcript
2020 Q4
17 Feb 21
Latest ownership filings
4
Catherine Moukheibir
19 Sep 23
4
ALEXANDER J DENNER
19 Sep 23
4
Sravan Kumar Emany
18 Sep 23
4
Ronald Silver
31 Aug 23
4
Ronald Silver
16 Aug 23
4
Minardo John
16 Aug 23
144
Notice of proposed sale of securities
11 Aug 23
144
Notice of proposed sale of securities
1 Aug 23
SC 13D
VectivBio Holding AG
7 Jul 23
SC 13G/A
WESTFIELD CAPITAL MANAGEMENT CO LP
5 Jul 23
Financial summary
Quarter (USD) | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 176.62 mm | 176.62 mm | 176.62 mm | 176.62 mm | 176.62 mm | 176.62 mm |
Cash burn (monthly) | 188.49 mm | 27.46 mm | 361.05 mm | 72.93 mm | (no burn) | (no burn) |
Cash used (since last report) | 530.97 mm | 77.35 mm | 1.02 bn | 205.43 mm | n/a | n/a |
Cash remaining | -354.35 mm | 99.27 mm | -840.45 mm | -28.81 mm | n/a | n/a |
Runway (months of cash) | -1.9 | 3.6 | -2.3 | -0.4 | n/a | n/a |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 249 |
Opened positions | 33 |
Closed positions | 33 |
Increased positions | 115 |
Reduced positions | 74 |
13F shares | Current |
---|---|
Total value | 1.67 tn |
Total shares | 165.01 mm |
Total puts | 3.00 k |
Total calls | 42.20 k |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 25.80 mm | $274.56 bn |
Sarissa Capital Management | 16.39 mm | $174.39 bn |
Vanguard | 14.85 mm | $157.97 bn |
STT State Street | 11.03 mm | $117.34 bn |
LSV Asset Management | 7.67 mm | $81.61 mm |
Credit Suisse | 5.80 mm | $61.72 bn |
Dimensional Fund Advisors | 5.61 mm | $59.70 bn |
Renaissance Technologies | 5.32 mm | $56.59 bn |
Brown Capital Management | 3.75 mm | $39.92 bn |
Victory Capital Management | 3.74 mm | $39.77 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Sep 23 | Sravan Kumar Emany | Class A Common Stock | Buy | Acquire P | No | No | 8.32 | 36,072 | 300.12 k | 188,730 |
15 Sep 23 | Denner Alexander J | Class A Common Stock | Grant | Acquire A | No | No | 0 | 1,798 | 0.00 | 118,930 |
15 Sep 23 | Moukheibir Catherine | Class A Common Stock | Grant | Acquire A | No | No | 0 | 2,098 | 0.00 | 127,061 |
29 Aug 23 | Ronald Silver | Class A Common Stock | Grant | Acquire A | No | No | 0 | 8,000 | 0.00 | 142,172 |
14 Aug 23 | Minardo John | Class A Common Stock | Sell | Dispose S | No | No | 10.04 | 7,045 | 70.73 k | 192,195 |
News
Why Terran Orbital Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
19 Sep 23
Orchestra BioMed, Vital Farms And Other Big Stocks Moving Higher On Tuesday
19 Sep 23
Stocks That Hit 52-Week Lows On Monday
11 Sep 23
Stocks That Hit 52-Week Lows On Friday
8 Sep 23
Stocks That Hit 52-Week Lows On Wednesday
6 Sep 23
Press releases
Ironwood Pharmaceuticals Reports Second Quarter 2023 Results; Raises Full Year 2023 LINZESS® U.S. Net Sales and Ironwood Revenue Guidance
8 Aug 23
Ironwood Pharmaceuticals to Host Second Quarter 2023 Investor Update Call
25 Jul 23
Ironwood and VectivBio Announce the Completion of the Tender Offer for VectivBio Shares
29 Jun 23